Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Liabilities and Shareholders Equity: 2017-2025

Historic Liabilities and Shareholders Equity for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $175.5 million.

  • Aclaris Therapeutics' Liabilities and Shareholders Equity fell 3.76% to $175.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $783.1 million, marking a year-over-year increase of 9.53%. This contributed to the annual value of $220.3 million for FY2024, which is 11.61% up from last year.
  • Per Aclaris Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $175.5 million for Q3 2025, which was down 7.20% from $189.1 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Liabilities and Shareholders Equity ranged from a high of $288.0 million in Q2 2021 and a low of $161.1 million during Q2 2024.
  • For the 3-year period, Aclaris Therapeutics' Liabilities and Shareholders Equity averaged around $198.3 million, with its median value being $197.4 million (2023).
  • Per our database at Business Quant, Aclaris Therapeutics' Liabilities and Shareholders Equity spiked by 266.46% in 2021 and then crashed by 31.65% in 2024.
  • Over the past 5 years, Aclaris Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $251.2 million in 2021, then increased by 1.35% to $254.6 million in 2022, then fell by 22.46% to $197.4 million in 2023, then increased by 11.61% to $220.3 million in 2024, then dropped by 3.76% to $175.5 million in 2025.
  • Its Liabilities and Shareholders Equity was $175.5 million in Q3 2025, compared to $189.1 million in Q2 2025 and $198.1 million in Q1 2025.